Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: Survey on coverage rate among elderly and chronic patients

被引:14
|
作者
Martinelli, Domenico [1 ,2 ]
Tafuri, Silvio [2 ,3 ]
Caputi, Giovanni [2 ,3 ]
Fortunato, Francesca [2 ,3 ]
Reggio, Paolo [4 ]
Germinario, Cinzia [2 ,3 ]
Prato, Rosa [1 ,2 ]
机构
[1] Univ Foggia, Sez Igine, Dipartimento Sci Med & Lavoro, I-71000 Foggia, Italy
[2] Epidemiol Observ Puglia Reg, Bari, Italy
[3] Univ Bari, Sect Hyg, Dept Biomed Sci & Human Oncol, Bari, Italy
[4] Sanofi Pasteur MSD SpA, Rome, Italy
关键词
Pneumococcal 23-valent polysaccharide vaccine; invasive pneumococcal disease; vaccination coverage rate; COST-EFFECTIVENESS; OLDER-ADULTS; REVACCINATION; PNEUMONIA; DISEASE;
D O I
10.1016/j.ajic.2009.09.019
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Streptococcus pneumoniae, lancet-shaped, gram-positive, facultative anaerobic organisms, are common inhabitants of the respiratory tract and may be isolated from the nasopharynx of 5% to 70% of healthy adults. Objective: The aims of the study were to estimate the vaccination coverage for pneumococcal 23-valent polysaccharide vaccine and to assess the impact its introduction in the Italian region of Puglia, where a program to provide this vaccination has been operative since 2000. Methods: Estimation of the coverage for pneumococcal 23-valent polysaccharide vaccine was implemented by a 2-step study consisting of data collection from local health unit vaccination registers between 2000 and 2008 in Puglia and of a cluster sampling study among general practitioners to validate routine data collected during the first step. Moreover, hospitalization for invasive pneumococcal diseases was studied. Results: From 2000 to 2004, among individuals >= 65 years, the overall coverage rate estimated by routine data amounted to 26.3%; between 2005 and 2007, annual coverage rates did not exceed 8%/year. Between 2002 and 2007, the overall coverage rate estimated by interviewing general practitioners was 46.6% (95% confidence interval: 39.9-53.4). The coverage rate in chronic patients by routine data was approximately 23%, whereas the rate provided by general practitioners was 17.6% (95% confidence interval: 12.5-22.8). From 2001 to 2007, hospitalization data did not show a reduction in invasive pneumococcal disease trends among the elderly population in Puglia. Conclusion: The results of this study demonstrate the need for improving vaccine coverage and implementing new immunization strategies and practices.
引用
收藏
页码:E8 / E15
页数:8
相关论文
共 50 条
  • [21] Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia
    Haggenburg, Sabine
    Garrido, Hannah M. Garcia
    Kant, Iris M. J.
    van der Straaten, Hanneke M.
    De Boer, Fransien
    Kersting, Sabina
    Issa, Djamila
    Te Raa, Doreen
    Visser, Hein P. J.
    Kater, Arnon P.
    Goorhuis, Abraham
    De Heer, Koen
    VACCINES, 2023, 11 (07)
  • [22] Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review
    Remschmidt, Cornelius
    Harder, Thomas
    Wichmann, Ole
    Bogdan, Christian
    Falkenhorst, Gerhard
    BMC INFECTIOUS DISEASES, 2016, 16
  • [23] Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
    Kazunari Satomura
    Toshitaka Nakahara
    Suketaka Iwanaga
    Megumi Noami
    Keiko Kusaka
    Kazuyoshi Harano
    BMC Health Services Research, 14 (Suppl 2)
  • [24] Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
    Vila-Corcoles, Angel
    Ochoa-Gondar, Olga
    Guzman, Jorge A.
    Rodriguez-Blanco, Teresa
    Salsench, Elisabet
    Fuentes, Cruz M.
    BMC INFECTIOUS DISEASES, 2010, 10
  • [25] Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older
    Angel Vila-Corcoles
    Olga Ochoa-Gondar
    Jorge A Guzmán
    Teresa Rodriguez-Blanco
    Elisabet Salsench
    Cruz M Fuentes
    BMC Infectious Diseases, 10
  • [26] The Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine in Adults Aged 50-80 Years
    Goldblatt, David
    Southern, Jo
    Andrews, Nick
    Ashton, Lindsey
    Burbidge, Polly
    Woodgate, Sarah
    Pebody, Richard
    Miller, Elizabeth
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (09) : 1318 - 1325
  • [27] A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
    Laratta, C. R.
    Williams, K.
    Vethanayagam, D.
    Ulanova, M.
    Vliagoftis, H.
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2017, 13
  • [28] Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China
    Zhao, Daijun
    Tobe, Ruoyan Gai
    Cui, Min
    He, Jinchun
    Wu, Bin
    VACCINE, 2016, 34 (50) : 6158 - 6165
  • [29] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
    Gouveia, Miguel
    Jesus, Goncalo
    Ines, Monica
    Costa, Joao
    Borges, Margarida
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 850 - 858
  • [30] Effectiveness of a 23-valent pneumococcal polysaccharide vaccine for the prevention of pneumococcal pneumonia in the elderly with chronic respiratory diseases: a case–control study of a single center
    Toshihiro Masuda
    Eiji Nakatani
    Toshihiro Shirai
    Taisuke Akamatsu
    Kanami Tamura
    Shingo Takahashi
    Yuko Tanaka
    Hirofumi Watanabe
    Yoshinari Endo
    Takahito Suzuki
    Mika Saigusa
    Akito Yamamoto
    Satoru Morita
    Yoko Sato
    Kazuhiro Asada
    BMC Pulmonary Medicine, 21